Prostate specific membrane antigen positron emission tomography in primary prostate cancer diagnosis: First-line imaging is afoot
Prostate specific membrane antigen positron emission tomography in primary prostate cancer diagnosis: First-line imaging is afoot
复制标题
DOI：
10.1016/j.canlet.2022.215883
复制
发表时间：
2022-08-27
期刊：
影响因子：
9.7
通讯作者：
Qin，Weijun
中科院分区：
文献类型：
--
作者：
Jiao，Jianhua;Zhang，Jingliang;Qin，Weijun
前列腺特异性膜抗原正电子发射断层扫描（PSMA PET）是一种很好的前列腺癌分子成像技术。目前，根据指南，PSMA PET用于原发性前列腺癌患者是对传统成像技术的补充。PSMA PET的这种补充功能是由于缺乏对其优势、局限性和潜在发展方向的系统综述。因此，我们回顾了PSMA配体、检测、T、N和M分期、治疗管理以及临床研究中PSMA PET的错误结果。我们还讨论了PSMA PET的优势和挑战。PSMA PET可大大提高前列腺癌的检出率和T/N/M分期的准确性，有利于原发性前列腺癌更合理的治疗。最后，我们提出PSMA PET可能成为原发性前列腺癌的一线成像方式，并描述了其潜在的扩展应用。
Prostate specific membrane antigen positron emission tomography (PSMA PET) is an excellent molecular imaging technique for prostate cancer. Currently, PSMA PET for patients with primary prostate cancer is supplementary to conventional imaging techniques, according to guidelines. This supplementary function of PSMA PET is due to a lack of systematic review of its strengths, limitations, and potential development direction. Thus, we review PSMA ligands, detection, T, N, and M staging, treatment management, and false results of PSMA PET in clinical studies. We also discuss the strengths and challenges of PSMA PET. PSMA PET can greatly increase the detection rate of prostate cancer and accuracy of T/N/M staging, which facilitates more appropriate treatment for primary prostate cancer. Lastly, we propose that PSMA PET could become the first-line imaging modality for primary prostate cancer, and we describe its potential expanded application.